丁酸氯倍他松，一种新型外用皮质类固醇：临床活性及其对垂体-肾上腺轴功能和表皮萎缩模型的影响
Clobetasone butyrate, a new topical corticosteroid: clinical activity and effects on pituitary-adrenal axis function and model of epidermal atrophy.
作者信息
Munro D D, Wilson L
出版信息
Br Med J. 1975 Sep 13;3(5984):626-8. doi: 10.1136/bmj.3.5984.626.
Abstract
Clobetasone butyrate is a new corticosteroid, selected for study because of its combination of good activity in the vasoconstriction test and low systemic activity in animals. Formulated as an 0.05% ointment and cream (Molivate) it was clinically effective in patients with eczema, its activity being significantly greater than that of hydrocortisone 1% or fluocortolone 0.2% (Ultradil). Under conditions that predispose to maximal percutaneous absorption clobetasone butyrate ointment had minimal effect on hypothalamic-pituitary-adrenal function. In an animal model of cutaneous atrophy it caused less thinning of the epidermis than steroids other than hydrocortisone. Clobetasone butyrate 0.05% ointment and cream gave every indication of offering clinically effective topical anti-inflammatory activity with a wide margin of safety.
摘要
丁酸氯倍他松是一种新型皮质类固醇，因其在血管收缩试验中具有良好活性且在动物体内全身活性较低而被选作研究对象。制成0.05%的软膏和乳膏（尤卓尔）后，对湿疹患者临床有效，其活性明显高于1%的氢化可的松或0.2%的氟轻松（优力肤）。在易于最大程度经皮吸收的条件下，丁酸氯倍他松软膏对下丘脑 - 垂体 - 肾上腺功能的影响极小。在皮肤萎缩的动物模型中，与除氢化可的松之外的其他类固醇相比，它引起的表皮变薄程度更小。0.05%的丁酸氯倍他松软膏和乳膏显示出具有临床有效的局部抗炎活性且安全性高。
相似文献
1
Clobetasone butyrate, a new topical corticosteroid: clinical activity and effects on pituitary-adrenal axis function and model of epidermal atrophy.丁酸氯倍他松，一种新型外用皮质类固醇：临床活性及其对垂体-肾上腺轴功能和表皮萎缩模型的影响
Br Med J. 1975 Sep 13;3(5984):626-8. doi: 10.1136/bmj.3.5984.626.
2
A separation of clinical from epidermal thinning effect in the topical glucocorticoid clobetasone butyrate.外用糖皮质激素丁酸氯倍他松临床效果与表皮变薄效果的分离。
Br J Dermatol. 1977 Jan;96(1):67-70. doi: 10.1111/j.1365-2133.1977.tb05187.x.
3
The effect of clobetasone butyrate and other topical steroids on skin thickness of the domestic pig.
Br J Dermatol. 1976 May;94(5):545-50. doi: 10.1111/j.1365-2133.1976.tb05144.x.
4
Halogenation and topical corticosteroids: a comparison between the 17-butyrate esters of hydrocortisone and clobetasone in ointment bases.卤化与外用皮质类固醇：氢化可的松和氯倍他松17-丁酸酯在软膏基质中的比较
Br J Dermatol. 1981 Feb;104(2):179-83. doi: 10.1111/j.1365-2133.1981.tb00042.x.
5
Clobetasone butyrate and hydrocortisone butyrate in the treatment of eczema: a double-blind comparison.丁酸氯倍他索和丁酸氢化可的松治疗湿疹的双盲比较。
Curr Med Res Opin. 1979;6(3):165-7. doi: 10.1185/03007997909109415.
6
Clinical evaluation of clobetasone butyrate in the treatment of children with atopic eczema, and its effect on plasma corticosteroid levels.丁酸氯倍他松治疗儿童特应性皮炎的临床评估及其对血浆皮质类固醇水平的影响。
Curr Med Res Opin. 1976;4(3):223-8. doi: 10.1185/03007997609109308.
7
Hypothalamic-pituitary-adrenal function in children with atopic dermatitis treated with clobetasone butyrate and its clinical evaluation.丁酸氯倍他松治疗儿童特应性皮炎的下丘脑-垂体-肾上腺功能及其临床评估
Int J Clin Pharmacol Ther Toxicol. 1985 Feb;23(2):118-20.
8
Eumovate (clobetasone butyrate 0.05%) cream: a review of clinical efficacy and safety.优力肤（丁酸氯倍他松0.05%）乳膏：临床疗效与安全性综述
J Dermatolog Treat. 2003 Jun;14(2):71-85. doi: 10.1080/09546630310004180.
9
Short- and long-term safety assessment of a two-compound ointment containing calcipotriene/betamethasone dipropionate (Taclonex/Daivobet/Dovobet ointment): hypothalamic-pituitary-adrenal axis function in patients with psoriasis vulgaris.含有卡泊三醇/倍他米松二丙酸酯的复方软膏（他卡西醇/得肤宝/达力士软膏）的短期和长期安全性评估：寻常型银屑病患者的下丘脑-垂体-肾上腺轴功能
J Drugs Dermatol. 2010 Aug;9(8):969-74.
引用本文的文献
1
Topical anti-inflammatory treatments for eczema: network meta-analysis.外用抗炎治疗湿疹：网状荟萃分析。
Cochrane Database Syst Rev. 2024 Aug 6;8(8):CD015064. doi: 10.1002/14651858.CD015064.pub2.
2
Predicting target-ligand interactions with graph convolutional networks for interpretable pharmaceutical discovery.基于图卷积网络的可解释药物发现靶标-配体相互作用预测。
Sci Rep. 2022 May 19;12(1):8434. doi: 10.1038/s41598-022-12180-x.
3
Strategies for using topical corticosteroids in children and adults with eczema.湿疹患儿和成人中局部皮质类固醇的使用策略。
Cochrane Database Syst Rev. 2022 Mar 11;3(3):CD013356. doi: 10.1002/14651858.CD013356.pub2.
4
Topical corticosteroid-induced skin atrophy: a comprehensive review.外用糖皮质激素引起的皮肤萎缩：综述
Drug Saf. 2015 May;38(5):493-509. doi: 10.1007/s40264-015-0287-7.
5
Epidermal thinning: evaluation of commercial corticosteroids.表皮变薄：市售皮质类固醇的评估
Arch Dermatol Res. 1980;267(1):7-24. doi: 10.1007/BF00416917.
6
Clinical evaluation of clobetasone butyrate: a comparative study of its effects in postoperative inflammation and on intraocular pressure.丁酸氯倍他松的临床评估：其对术后炎症及眼压影响的比较研究
Br J Ophthalmol. 1980 Jan;64(1):43-5. doi: 10.1136/bjo.64.1.43.
7
Sexual misconduct.性行为不端。
CMAJ. 1987 Dec 15;137(12):1078-80.
8
Seizure during urologic procedure.泌尿外科手术期间癫痫发作。
CMAJ. 1988 Feb 15;138(4):302-3.
9
Long-term treatment with 0-01% fluclorolone acetonide in children.0.01%氟轻松丙酮奈德用于儿童的长期治疗。
Br Med J. 1976 Mar 13;1(6010):627. doi: 10.1136/bmj.1.6010.627.
10
Hydrocortisone 17-butyrate: a new topical corticosteroid preliminary report.氢化可的松17-丁酸酯：一种新型外用皮质类固醇的初步报告。
Drugs. 1976;12(4):249-57. doi: 10.2165/00003495-197612040-00001.
本文引用的文献
1
BETAMETHASONE 17-VALERATE: A NEW TOPICAL CORTICOSTEROID.倍他米松17-戊酸酯：一种新型外用皮质类固醇。
Lancet. 1964 May 30;1(7344):1177-9. doi: 10.1016/s0140-6736(64)91205-x.
2
Percutaneous absorption of hydrocortisone in children.氢化可的松在儿童中的经皮吸收
Am J Dis Child. 1966 Sep;112(3):218-24. doi: 10.1001/archpedi.1966.02090120086008.
3
Vasoconstrictor and systemic activities of topical steroids.局部用类固醇的血管收缩作用及全身活性
Arch Dermatol. 1968 Apr;97(4):407-10.
4
The clinical evaluation of a new topical corticosteroid, clobetasol propionate. An international controlled trial.
Br J Dermatol. 1974 Feb;90(2):197-203. doi: 10.1111/j.1365-2133.1974.tb06385.x.
5
Pustular psoriasis with adrenal suppression following topical corticosteroids.外用糖皮质激素后出现肾上腺抑制的脓疱型银屑病。
Proc R Soc Med. 1974 Aug;67(8):719-20. doi: 10.1177/003591577406700813.
6
Pituitary-adrenal function after occlusive topical therapy with betamethasone-17-valerate.倍他米松-17-戊酸酯局部封闭治疗后的垂体-肾上腺功能
Lancet. 1967 Nov 18;2(7525):1059-61. doi: 10.1016/s0140-6736(67)90336-4.
Zotero 插件